Leukaemia Trial, Recruiting NCT06867289 Sponsor: Centre Hospitalier Régional Metz-Thionville Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT06867289
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your child needs a brain MRI scan at CHR de Metz-Thionville and has been recommended sedation (a calming medication called DEX) to help them stay still during the scan
  • Your child is between 12 months and 5 years old, OR is between 5 and 18 years old but may have difficulty cooperating during the scan (for example, due to a previous failed MRI attempt or autism spectrum disorder)
  • Your child is covered by a social security (health insurance) scheme
  • You, as the child's legal guardian(s), have given your free and informed consent to take part

Who may not be able to join:

  • Children who weigh less than 10 kg
  • Children who have a known allergy or sensitivity to the sedation medication (DEX) or any of its ingredients
  • Children who have a significant heart conduction problem (advanced heart block, level 2 or 3) and do not have a pacemaker fitted
  • Children who have blood pressure that is too low and not being controlled
  • Children who have an acute (sudden/recent) brain or blood vessel condition (confirm with trial site)
  • Children who have a blocked nose
  • Children whose parent or guardian refuses the sedation medication (DEX)
  • Children who are under legal guardianship
  • Children who are subject to a judicial order or sanction

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anne-Charlotte CULLIER, MD, CHR Metz Thionville Hopital Femme Mère Enfant

Phone: 0033387557766

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Régional Metz-Thionville
Registry
ClinicalTrials.gov
Start date
8 April 2025
Est. completion
8 April 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Prediction of complete NMRI success

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov